



Your Health Matters

Nutrition & Prostate Cancer References

1. Byers, T, Nestle, M, McTiernan, A, Doyle, C, Currie-Williams, A, Gansler, T, et al. American Cancer Society 2001 Nutrition and Physical Activity Guidelines Advisory Committee. (2002). American Cancer Society guidelines on nutrition and physical activity for cancer prevention: Reducing the risk of cancer with healthy food choices and physical activity. *CA: A Cancer Journal for Clinicians*, 52(2), 92-119.
2. Heber, D., Fair, W., & Ornish, D. Capcure. (1999). Nutrition & Prostate Cancer: A Monograph from the CaP CURE Nutrition Project. 2nd edition. January <http://www.capcure.org.il/abstracts/pub-pdf/nutrition.pdf>.
3. Frattaroli, J., Weidner, G., Dnistrian, A.M., Kemp, C., Daubenmier, J.J., Marlin, R.O., et al. (2008). Clinical events in prostate cancer lifestyle trial: results from two years of follow-up. *Urology*, Dec;72(6), 1319-1323.
4. Ornish, D., Weidner, G., Fair, W.R., Marlin, R., & Pettengill, E.B. (2005). Intensive lifestyle changes may affect the progression of prostate cancer. *Journal of Urology*, 174(3), 1065-1069.
5. Saxe, G.A., Major, J.M., Nguyen, J.Y., Freeman, K.M., & Downs, T.M. (2006). Potential attenuation of disease progression in recurrent prostate cancer with plant-based diet and stress reduction. *Integrative Cancer Therapies*, 5(3), 206-213.
6. Dubenmier, J.J., Weidner, G., Marlin, R., Crutchfield, L., & Dunn-Emke, S. (2006). Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance. *Urology*, 67(1), 125-130.
7. Sunny, L. (2005). A low fat diet rich in fruits and vegetables may reduce the risk of developing prostate cancer. *Asian Pacific Journal of Cancer Prevention*, 6(4),490-496.
8. Khaw, K.T., Bingham, S., Welch, R.L.A., Wareham, N., Oakes, S., Day, N., et al. (2001). The European Prospective Investigation into Cancer and Nutrition. Relation between plasma ascorbic acid and mortality in men and women in EPIC-Norfolk prospective study: a prospective population study. *Lancet*, 357, 657-663.
9. Willett, W.C. (2000). Intakes of fruits, vegetables and related nutrients and the risk of non-Hodgkin's lymphoma among women. *Cancer Epidemiology Biomarkers and Prevention*, 9, 477-485.
10. U.S. Dept. of Agriculture. (1995). Nutrition and your health: Dietary Guidelines for Americans, ed. 4, Home & Garden Bulletin No. 232, Washington DC, U.S. Dept. of Health and Human Services.
11. World Cancer Research Fund/American Institute for Cancer Research. Food, nutrition and the prevention of cancer: A global perspective. Washington, DC: American Institute for Cancer Research, 1997.
12. Steinmetz, K.A., & Potter, J.D. (1996). Vegetables, fruit, and cancer prevention: a review. *Journal of American Dietetic Association*, 96, 1027-1039.
13. Zhang, S., Hunter, D.J., Forman, M.R., Rosner, B.A., Speizer, F.E., Colditz, G.A., et al. (1999). Dietary carotenoids and vitamins A, C, and E and risk of breast cancer. *Journal of the National Cancer Institute*, 91, 547-556.
14. Zhang, S.M., Hunter, D.J., Rosner, B.A., Giovannucci, E.L., Colditz, G.A., Speizer, F.E., et al. (2000). Intakes of fruits, vegetables, and related nutrients and the risk of non-Hodgkin's lymphoma among women. *Cancer Epidemiology Biomarkers and Prevention*, 9(5), 477-485.

15. Freudenheim, J.L., Marshall, J.R., Vena, J.E., Laughlin, R., Brasure, J.R., Swanson, M.K., et al. (1996). Premenopausal breast cancer risk and intake of vegetables, fruits, and related nutrients. *Journal of the National Cancer Institute*, 88, 340-348.
16. Rock, Cl., Saxe, G.A., Ruffin, M.T. 4th, August, D.A., & Schottenfeld, D. (1996). Carotenoids, vitamin A, and estrogen receptor status in breast cancer. *Nutrition and Cancer*, 25(3), 281-296.
17. Eastwood, M.A. (1999). Interaction of dietary antioxidants in vivo: How fruit and vegetables prevent disease? *Quarterly Journal of Medicine*, (92), 527-530.
18. Voorrips, L.E., Goldbohm, R.A., Brants, H.A., van Poppel, G.A., Sturmans, F., Hermus, R.J., et al. (2000). A prospective cohort study on antioxidant and folate intake and male lung cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, 9, 357-365.
19. Nguyen, J.Y., Major, J.M., Knott, C.J., Freeman, K.M., & Downs, T.M. (2006). Adoption of a plant-based diet by patients with recurrent prostate cancer. *Integrative Cancer Therapies*, 5(3), 214-223.
20. Hodge, A.M., English, D.R., McCredie, M.R., Severi, G., Boyle, P., Hopper, J.L., et al. (2004). Foods, nutrients and prostate cancer. *Cancer Causes Control*, 15(1), 11-20.
21. Cohen, J.H., Kristal, A.R., & Stanford, J.L. (2000). Fruit and vegetable intakes and prostate cancer risk. *Journal of the National Cancer Institute*, 92(1), 61-68.
22. Jain, M.G., Hislop, G.T., Howe, G.R., & Ghadirian, P. (1999). Plant foods, antioxidants, and prostate cancer risk: findings from case-control studies in Canada. *Nutrition and Cancer*, 34(2), 173-184.
23. Deneo-Pellegrini, H., De Stefani, E., Ronco, A., & Mendilaharsu, M. (1999). Foods, nutrients and prostate cancer: a case-control study in Uruguay. *British Journal of Cancer*, 80(3-4), 591-597.
24. Smit, E., Garcia-Palmieri, M.R., Figueroa, N.R., McGee, D.L., Messina, M., Freudenheim, J.L., et al. (2007). Protein and legume intake and prostate cancer mortality in Puerto Rican men. *Nutrition and Cancer*, 58(2), 146-152.
25. Kirsh, V.A., Peters, U., Mayne, S.T., Subar, A.F., Chatterjee, N., Johnson, C.C., et al.; Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. (2007). Prospective study of fruit and vegetable intake and risk of prostate cancer. *Journal of the National Cancer Institute*, 99(15), 1200-1209.
26. Bin Hafeez, B., Asim, M., Siddiqui, I.A., Adhami, V.M., Murtaza, I., & Mukhtar, H. (2008). Delphinidin, a dietary anthocyanidin in pigmented fruits and vegetables: a new weapon to blunt prostate cancer growth. *Cell Cycle*, 7(21), 3320-3326.
27. Key, T.J., Silcocks, P.B., Davey, G.K., Appleby, P.N., & Bishop, D.T. (1997). A case-control study of diet and prostate cancer. *British Journal of Cancer*, 76(5), 678-687.
28. Hsing, A.W., Chokkalingam, A.P., Gao, Y.T., Madigan, M.P., Deng, J., Gridley, G., et al. (2002). Allium vegetables and risk of prostate cancer: a population-based study. *Journal of the National Cancer Institute*, 94(21), 1648-1651.
29. Pinto, J.T., & Rivlin, R.S. (2001). Antiproliferative effects of allium derivatives from garlic. *The Journal of Nutrition*, 131(3s), 1058S-1060S.
30. Fleischauer, A.T., & Arab, L. (2001). Garlic and cancer: a critical review of the epidemiologic literature. *The Journal of Nutrition*, (3s), 1032S-1040S.
31. Kolonel, L.N., Hankin, J.H., Whittemore, A.S., Wu, A.H., Gallagher, R.P., Wilkens, L.R., et al. (2000). Vegetables, fruits, legumes and prostate cancer: a multiethnic case-control study. *Cancer Epidemiology Biomarkers Prevention*, 9(8), 795-804.
32. Wu, K., Erdman, J.W. Jr, Schwartz, S.J., Platz, E.A., Leitzmann, M., Clinton, S.K., et al. (2004). Plasma and Dietary Carotenoids, and the Risk of Prostate Cancer: A Nested Case-Control Study. *Cancer Epidemiology Biomarkers and Prevention*, 13(2), 260-269.
33. Ohno, Y., Yoshida, O., Oishi, K., Okada, K., Yamabe, H., Schroeder, F.H., et al. (1998). Dietary beta-carotene and cancer of the prostate: a case-control study in Kyoto, Japan. *Cancer Research*, 48(5), 1331-1336.
34. Bosetti, C., Tzonou, A., Laggiou, P., Negri, E., Trichopoulos, D., & Hsieh, C.C., et al. (2000). Fraction of prostate cancer incidence attributed to diet in Athens, Greece. *European Journal of Cancer Prevention*, 9(2), 119-123.

35. Norrish, A.E., Jackson, R.T., Sharpe, S.J., & Skeaff, C.M. (2000). Prostate cancer and dietary carotenoids. *American Journal of Epidemiology*, 151(2), 119-123.
36. Tzonou, A., Signorello, L.B., Lagiou, P., Wu, J., Trichopoulos, D., & Trichopoulou, A. (1999). Diet and cancer of the prostate: a case-control study in Greece. *International Journal of Cancer*, 80(5), 704-708.
37. Giovannucci, E., Ascherio, A., Rimm, E.B., Stampfer, M.J., Colditz, G.A., Willett, W.C., et al. (1995). Intake of carotenoids and retinol in relation to risk of prostate cancer. *Journal of the National Cancer Institute*, 87(23), 1767-1776.
38. Daviglus, M.L., Dyer, A.R., Persky, V., Chavez, N., Drum, M., Goldberg, J., et al. (1996). Dietary beta-carotene, vitamin C, and risk of prostate cancer: results from the Western Electric Study. *Epidemiology*, 7(5), 472-477.
39. Chang, S., Erdman, J.W. Jr, Clinton, S.K., Vadiveloo, M., Strom, S.S., et al. (2005). Relationship between plasma carotenoids and prostate cancer. *Nutrition and Cancer*, 53(2), 127-134.
40. Watters, J.L., Gail, M.H., Weinstein, S.J., Virtamo, J., & Albanes, D. (2009). Associations between alpha-tocopherol, beta-carotene, and retinol and prostate cancer survival. *Cancer Research*, 69(9), 3833-3841.
41. Schuurman, A.G., Goldbohm, R.A., Brants, H.A., & van den Brandt, P.A. (2002). A prospective cohort study on intake of retinol, vitamins C and E, and carotenoids and prostate cancer risk (Netherlands). *Cancer Causes Control*, 13(6), 573-582.
42. Omenn, G.S., Goodman, G.E., Thornquist, M.D., Balmes, J., Cullen, M.R., Glass, A., et al. (1996). Risk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. *Journal of the National Cancer Institute*, 88(21), 1550-1559.
43. Hennekens, C.H., Buring, J.E., Manson, J.E., Stampfer, M., Rosner, B., Cook, N.R., et al. (1996). Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease. *The New England Journal of Medicine*, 334(18), 1145-1149.
44. Heinonen, O.P., Albanes, D., Virtamo, J., Taylor, P.R., Huttunen, J.K., Hartman, A.M., et al. (1998). Prostate cancer and supplementation with alpha-tocopherol and beta-carotene: incidence and mortality in a controlled trial. *Journal of the National Cancer Institute*, 90(6), 440-446.
45. Wang, L., Liu, D., Ahmed, T., Chung, F.L., Conaway, C., Chiao, J.W., et al. (2004). Targeting cell cycle machinery as a molecular mechanism of sulforaphane in prostate cancer prevention. *International Journal of Oncology*, 24(1), 187-192.
46. Chinni, S.R., Li, Y., Upadhyay, S., Koppolu, P.K., Sarkar, F.H. (2001). Indole-3-carbinol (I3C) induced cell growth inhibition, G1 cell cycle arrest and apoptosis in prostate cancer cells. *Oncogene*, 20(23), 2927-2936.
47. Canene-Adams, K., Lindshield, B.L., Wang, S., Jeffrey, E.H., Clinton, S.K., et al. (2007). Combinations of Tomato and Broccoli Enhance Antitumor Activity in Dunning R3327-H Prostate Adenocarcinomas. *Cancer Research*, 67(2), 836-843.
48. Bhamre, S., Sahoo, D., Tibshirani, R., Dill, D.L., & Brooks, J.D. (2009). Temporal changes in gene expression induced by sulforaphane in human prostate cancer cells. *Prostate*, 69(2), 181-190.
49. Steinbrecher, A., Nimptsch, K., Hüsing, A., Rohrmann, S., & Linseisen, J. (2009). Dietary glucosinolate intake and risk of prostate cancer in the EPIC-Heidelberg cohort study. *International Journal of Cancer*, 125(9), 2179-2186.
50. Garikapaty, V.P., Ashok, B.T., Tadi, K., Mittelman, A., & Tiwari, R.K. (2006). 3,3'-Diindolylmethane downregulates pro-survival pathway in hormone independent prostate cancer. *Biochemical and Biophysical Research Communications*, 340(2), 718-725.
51. Chinnakannu, K., Chen, D., Li, Y., Wang, Z., Dou, Q.P., Reddy, G.P., & Sarkar, F.H. (2009). Cell cycle-dependent effects of 3,3'-diindolylmethane on proliferation and apoptosis of prostate cancer cells. *Journal of Cell Physiology*, 219(1), 94-99.
52. Traka, M., Gasper, A.V., Melchini, A., Bacon, J.R., Needs, P.W., Frost, V., et al. (2008). Broccoli consumption interacts with GSTM1 to perturb oncogenic signalling pathways in the prostate. *PLoS ONE*, 3(7), e2568.
53. Ellinger, S., Ellinger, J., & Stehle, P. (2006). Tomatoes, tomato products and lycopene in the prevention and treatment of prostate cancer: do we have the evidence from intervention studies? *Current Opinion in Clinical Nutrition and Metabolic Care*, 9(6), 722-727.
54. Fraser, M.L., Lee, A.H., & Binns, C.W. (2005). Lycopene and prostate cancer: emerging evidence. *Expert Review of Anticancer Therapy*, 5(5), 847-854.

55. Bowen, P., Chen, L., Stacewicz-Sapuntzakis, M., Duncan, C., Sharifi, R., Ghosh, L., et al. (2002). Tomato sauce supplementation and prostate cancer: lycopene accumulation and modulation of biomarkers of carcinogenesis. *Experimental Biology and Medicine* (Maywood), 227(10), 886-893.
56. Chen, L., Stacewicz-Sapuntzakis, M., Duncan, C., Sharifi, R., Ghosh, L., van Breemen, R., et al. (2001). Oxidative DNA damage in prostate cancer patients consuming tomato sauce-based entrees as a whole-food intervention. *Journal of the National Cancer Institute*, 93(24), 1872-1879.
57. Chan, J.M., Holick, C.N., Leitzmann, M.F., Rimm, E.B., Willett, W.C., et al. (2006). Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). *Cancer Causes Control*, 17(2), 199-208.
58. Giovannucci, E., Liu, Y., Platz, E.A., Stampfer, M.J., & Willett, W.C. (2007). Risk factors for prostate cancer incidence and progression in the health professionals follow-up study. *International Journal of Cancer*, 121(7), 1571-1578.
59. Key, T.J., Appleby, P.N., Allen, N.E., Travis, R.C., Roddam, A.W., Jenab, M., et al. (2007). Plasma carotenoids, retinol, and tocopherols and the risk of prostate cancer in the European Prospective Investigation into Cancer and Nutrition study. *American Journal of Clinical Nutrition*, 86(3), 672-681.
60. Kim, H.S., Bowen, P., Chen, L., Duncan, C., Ghosh, L., Sharifi, R., et al. (2003). Effects of tomato sauce consumption on apoptotic cell death in prostate benign hyperplasia and carcinoma. *Nutrition and Cancer*, 47(1), 40-47.
61. Vaishampayan, U., Hussain, M., Banerjee, M., Seren, S., Sarkar, F.H., Fontana, J., et al. (2007). Lycopene and soy isoflavones in the treatment of prostate cancer. *Nutrition and Cancer*, 59(1), 1-7.
62. Bunker, C.H., McDonald, A.C., Evans, R.W., de la Rosa, N., Boumosleh, J.M., & Patrick, A.L. (2007). A randomized trial of lycopene supplementation in Tobago men with high prostate cancer risk. *Nutrition and Cancer*, 57(2), 130-137.
63. Jatoi, A., Burch, P., Hillman, D., Vanyo, J.M., Dakhil, S., Nikcevich, D., et al.; North Central Cancer Treatment Group. A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer: results of a Phase II study from the North Central Cancer Treatment Group. *Urology*, 69(2), 289-294.
64. Jian, L., Lee, A.H., & Binns, C.W. (2007). Tea and lycopene protect against prostate cancer. *Asia Pacific Journal of Clinical Nutrition*, 16 Suppl 1, 453-457.
65. Kucuk, O., Sarkar, F.H., Djuric, Z., Sakr, W., Pollak, M.N., Khachik, F., et al. (2002). Effects of lycopene supplementation in patients with localized prostate cancer. *Experimental Biology and Medicine* (Maywood), 227(10), 881-885.
66. Kanagaraj, P., Vijayababu, M.R., Ravisankar, B., Anbalagan, J., Aruldas, M.M., & Arunakaran, J. (2007). Effect of lycopene on insulin-like growth factor-I, IGF binding protein-3 and IGF type-I receptor in prostate cancer cells. *Journal of Cancer Research and Clinical Oncology*, 133(6), 351-359.
67. Hwang, E.S., & Bowen, P.E. (2002). Can the consumption of tomatoes or lycopene reduce cancer risk? *Integrative Cancer Therapies*, 1(2), 121-132.
68. Lu, Q.Y., Hung, J.C., Heber, D., Go, V.L., Reuter, V.E., Cordon-Cardo, C., et al. (2001). Inverse associations between plasma lycopene and other carotenoids and prostate cancer. *Cancer Epidemiology Biomarkers Prevention*, 10(7), 749-756.
69. Gann, P.H., Ma, J., Giovannucci, E., Willett, W., Sacks, F.M., Hennekens, C.H., et al. (1999). Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis. *Cancer Research*, 59(6), 1225-1230.
70. Zhang, J., Dhakal, I., Stone, A., Ning, B., Greene, G., Lang, N.P., & Kadlubar, F.F. (2007). Plasma carotenoids and prostate cancer: a population-based case-control study in Arkansas. *Nutrition and Cancer*, 59(1), 46-53.
71. Boileau, T.W., Liao, Z., Kim, S., Lemeshow, S., Erdman, J.W., Jr, Clinton, S.K. et al. (2003). Prostate carcinogenesis in N-methyl-N-nitrosourea (NMU)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. *Journal of the National Cancer Institute*, 95(21), 1578-1586.
72. Weisburger, J.H. (1998). Evaluation of the evidence on the role of tomato products in disease prevention. *Proceedings of the Society for Experimental Biology and Medicine*, 218(2), 140-143.
73. Malik, A., Afaq, F., Sarfaraz, S., Adhami, V.M., Syed, D.N., et al. (2005). Pomegranate fruit juice for chemoprevention and chemotherapy of prostate cancer. *Proceedings of the National Academy of Sciences USA*, 102(41), 14813-14818.
74. Toi, M., Bando, H., Ramachandran, C., Melnick, S.J., Imai, A., Fife, R.S., et al. (2003). Preliminary studies on the anti-angiogenic potential of pomegranate fractions in vitro and in vivo. *Angiogenesis*, 6(2), 121-128.

75. Sartippour, M.R., Seeram, N.P., Rao, J.Y., Moro, A., Harris, D.M., Henning, S.M., et al. (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. *International Journal of Oncology*, 32(2), 475-480.
76. Hong, M.Y., Seeram, N.P., & Heber, D. (2008). Pomegranate polyphenols down-regulate expression of androgen-synthesizing genes in human prostate cancer cells overexpressing the androgen receptor. *Journal of Nutritional Biochemistry*, 19(12), 848-855.
77. Rettig, M.B., Heber, D., An, J., Seeram, N.P., Rao, J.Y., Liu, H., et al. (2008). Pomegranate extract inhibits androgen-independent prostate cancer growth through a nuclear factor-kappaB-dependent mechanism. *Molecular Cancer Therapeutics*, 7(9), 2662-2671.
78. Pantuck, A.J., Leppert, J.T., Zomorodian, N., Aronson, W., Hong, J., et al. (2006). Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. *Clinical Cancer Research*, 12(13), 4018-4026.
79. Lombardi-Boccia, G., Lucarini, M., Lanzi, S., Aguzzi, A., & Cappelloni, M. (2004). Nutrients and antioxidant molecules in yellow plums (*Prunus domestica* L.) from conventional and organic productions: a comparative study. *Journal of Agricultural Food Chemistry*, 52(1), 90-94.
80. Grindler-Pedersen, L., Rasmussen, S.E., Bugel, S., Jorgensen, L.V., Dragsted, L.O., et al. (2003). Effect of diets based on foods from conventional versus organic production on intake and excretion of flavonoids and markers of antioxidative defense in humans. *Journal of Agricultural Food Chemistry*, 51(19), 5671-5676.
81. Asami, D.K., Hong, Y.J., Barrett, D.M., & Mitchell, A.E. (2003). Comparison of the total phenolic and ascorbic acid content of freeze-dried and air-dried marionberry, strawberry, and corn grown using conventional, organic, and sustainable agricultural practices. *Journal of Agricultural Food Chemistry*, 51(5), 1237-1241.
82. Baxter, G.J., Graham, A.B., Lawrence, J.R., Wiles, D., & Paterson, J.R. (2001). Salicylic acid in soups prepared from organically and non-organically grown vegetables. *European Journal of Nutrition*, 40(6), 289-292.
83. Ferreres, F., Valentao, P., Llorach, R., Pinheiro, C., Cardoso, L., Pereira, J.A., et al. (2005). Phenolic compounds in external leaves of tronchuda cabbage (*Brassica oleracea* L. var. *costata* DC). *Journal of Agricultural Food Chemistry*, 53(8), 2901-2907.
84. Harris, P.J., Robertson, A.M., Watson, M.E., Triggs, C.M., & Ferguson, L.R. (1993). The effects of soluble-fiber polysaccharides on the adsorption of a hydrophobic carcinogen to an insoluble dietary fiber. *Nutrition and Cancer*, 19(1), 43-54.
85. Slavin, J.L. (2000). Mechanisms for the impact of whole grain foods on cancer risk. *Journal of the American College of Nutrition*, 19(3 Suppl), 300S-307S.
86. Slavin, J. (2003). Why whole grains are protective: biological mechanisms. *The Proceedings Nutrition Society*, 62(1), 129-134.
87. Tariq, N., Jenkins, D.J., Vidgen, E., Fleshner, N., Kendall, C.W., Story, J.A., et al. (2000). Effect of soluble and insoluble fiber diets on serum prostate specific antigen in men. *Journal of Urology*, 163(1), 114-118.
88. Tymchuk, C.N., Barnard, R.J., Heber, D., & Aronson, W.J. (2001). Evidence of an inhibitory effect of diet and exercise on prostate cancer cell growth. *The Journal of Urology*, 166(3), 1185-1189.
89. Pelucchi, C., Talamini, R., Galeone, C., Negri, E., Franceschi, S., Dal Maso, L., et al. (2004). Fibre intake and prostate cancer risk. *International Journal of Cancer*, 109(2), 278-280.
90. La Vecchia, C., Chatenoud, L., Negri, E., & Franceschi, S. (2003). Session: whole cereal grains, fibre and human cancer wholegrain cereals and cancer in Italy. *The Proceedings Nutrition Society*, 62(1), 45-49.
91. Park, S.Y., Murphy, S.P., Wilkens, L.R., Henderson, B.E., & Kolonel, L.N.; Multiethnic Cohort Study. (2008). Legume and isoflavone intake and prostate cancer risk: The Multiethnic Cohort Study. *International Journal of Cancer*, 123(4), 927-932.
92. Suzuki, R., Allen, N.E., Key, T.J., Appleby, P.N., Tjønneland, A., Johnsen, N.F., et al. (2009). A prospective analysis of the association between dietary fiber intake and prostate cancer risk in EPIC. *International Journal of Cancer*, 124(1), 245-249.

93. Hebert, J.R., Hurley, T.G., Olendzki, B.C., Teas, J., Ma, Y., Hampl, J.S., et al. (1998). Nutritional and socioeconomic factors in relation to prostate cancer mortality: a cross-national study. *Journal of the National Cancer Institute*, 90, 1637-1647.
94. Shike, M., Laskany, L., Riedel, E., Fleisher, M., Schatzkin, A., Lanza, E., et al. (2002). Lack of effect of a low-fat, high-fruit, -vegetable, and -fiber diet on serum prostate-specific antigen of men without prostate cancer: results from a randomized trial. *Journal of Clinical Oncology*, 20(17), 3592-3598.
95. Stoll, B.A. (1996). Can supplementary dietary fibre suppress breast cancer growth? *British Journal of Cancer*, 73(5), 557-559.
96. Venkateswaran, V., Haddad, A.Q., Fleshner, N.E., Fan, R., Sugar, L.M., Nam, R., et al. (2007). Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. *Journal of the National Cancer Institute*, 99(23), 1793-1800.
97. Hsing, A.W., Chua, S. Jr., Gao, Y.T., Gentschein, E., Chang, L., Deng, J., et al. (2001). Prostate cancer risk and serum levels of insulin and leptin: a population-based study. *Journal of the National Cancer Institute*. May 93(10), 783-789.
98. Barnard, R.J., Ngo, T.H., Leung, P.S., Aronson, W.J., & Golding, L.A. (2003). A low-fat diet and/or strenuous exercise alters the IGF axis in vivo and reduces prostate tumor cell growth in vitro. *Prostate*, 56(3), 201-206.
99. Ngo, T.H., Barnard, R.J., Tymchuk, C.N., Cohen, P., & Aronson, W.J. (2002). Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States). *Cancer Causes Control*, 13(10), 929-935.
100. Moyad, M.A. (2003). The use of complementary/preventive medicine to prevent prostate cancer recurrence/progression following definitive therapy: part I--lifestyle changes. *Current Opinion in Urology*, 13(2), 137-145.
101. Aksoy, Y., Aksoy, H., Bakan, E., Atmaca, A.F., & Akcay, F. (2004). Serum insulin-like growth factor-I and insulin-like growth factor-binding protein-3 in localized, metastasized prostate cancer and benign prostatic hyperplasia. *Urologia Internationalis*, 72(1), 62-65.
102. Yu, H., & Berkel, H. (1999). Insulin-like growth factors and cancer. *Journal of the Louisiana State Medical Society*, 151(4), 218-223.
103. Li, L., Yu, H., Schumacher, F., Casey, G., & Witte, J.S. (2003). Relation of serum insulin-like growth factor-I (IGF-I) and IGF binding protein-3 to risk of prostate cancer (United States). *Cancer Causes Control*, 14(8), 721-726.
104. Cardillo, M.R., Monti, S., Di Silverio, F., Gentile, V., Sciarra, F., Toscano, V., et al. (2003). Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. *Anticancer Research*, 23(5A), 3825-3835.
105. Kaaks, R., & Lukanova, A. (2001). Energy balance and cancer: the role of insulin and insulin-like growth factor-I. *Proceedings of the Nutrition Society*, 60(1), 91-106.
106. Albanes, D., Weinstein, S.J., Wright, M.E., Männistö, S., Limburg, P.J., Snyder, K., et al. (2009). Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer. *Journal of the National Cancer Institute*, 101(18), 1272-1279.
107. Roddam, A.W., Allen, N.E., Appleby, P., Key, T.J., Ferrucci, L., Carter, H.B., et al. (2008). Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. *Annals of Internal Medicine*, 149(7), 461-471.
108. Spentzos, D., Mantzoros, C., Regan, M.M., Morrissey, M.E., Duggan, S., Flickner-Garvey, S., et al. (2003). Minimal effect of a low-fat/high soy diet for asymptomatic, hormonally naive prostate cancer patients. *Clinical Cancer Research*, 9(9), 3282-3287.
109. Habito, R.C., & Ball, M.J. (2001). Postprandial changes in sex hormones after meals of different composition. *Metabolism*, 50(5), 505-511.
110. Fleshner, N., Bagnell, P.S., Klotz, L., & Venkateswaran, V. (2004). Dietary fat and prostate cancer. *The Journal of Urology*, 171(2 Pt 2), S19-S24.
111. Veierod, M.B., Laake, P., & Thelle, D.S. (1997). Dietary fat intake and risk of prostate cancer: a prospective study of 25,708 Norwegian men. *International Journal of Cancer*, 73(5), 634-638.
112. Bairati, I., Meyer, F., Fradet, Y., & Moore, L. (1998). Dietary fat and advanced prostate cancer. *The Journal of Urology*, 159(4), 1271-1275.

113. Meyer, F., Bairati, I., Shadmani, R., Fradet, Y., & Moore, L. (1999). Dietary fat and prostate cancer survival. *Cancer Causes Control*, 10(4), 245-251.
114. Le Marchand, L., Hankin, J.H., Kolonel, L.N., & Wilkens, L.R. (1991). Vegetable and fruit consumption in relation to prostate cancer risk in Hawaii: a reevaluation of the effect of dietary beta-carotene. *American Journal of Epidemiology*, 133(3), 215-219.
115. Giovannucci, E., Rimm, E.B., Colditz, G.A., Stampfer, M.J., Ascherio, A., Chute, C.C., et al. (1993). A prospective study of dietary fat and risk of prostate cancer. *Journal of the National Cancer Institute*, 85(19), 1571-1579.
116. Neuhauser, M.L., Barnett, M.J., Kristal, A.R., Ambrosone, C.B., King, I., Thornquist, M., et al. (2007). (n-6) PUFA increase and dairy foods decrease prostate cancer risk in heavy smokers. *Journal of Nutrition*, 137(7), 1821-1827.
117. Colli, J.L., & Colli, A. (2005). Comparisons of prostate cancer mortality rates with dietary practices in the United States. *Urologic Oncology*, 23(6), 390-398.
118. Williams, G.M., Williams, C.L., & Weisburger, J.H. (1999). Diet and cancer prevention: the fiber first diet. *Toxicological Sciences*, 52(2 Suppl), 72-86.
119. Lee, M.M., Wang, R.T., Hsing, A.W., Gu, F.L., Wang, T., Spitz, M., et al. (1998). Case-control study of diet and prostate cancer in China. *Cancer Causes Control*, 9(6), 545-552.
120. Kushi, L., & Giovannucci, E. (2002). Dietary fat and cancer. *The American Journal of Medicine*, 113 Suppl 9B, 63S-70S.
121. Meyer, F., Bairati, I., Fradet, Y., & Moore, L. (1997). Dietary energy and nutrients in relation to preclinical prostate cancer. *Nutrition Cancer*, 29(2), 120-126.
122. Fradet, Y., Meyer, F., Bairati, I., Shadmani, R., & Moore, L. Dietary fat and prostate cancer progression and survival. *European Urology*, 35(5-6), 388-391.
123. Michaud, D.S., Augustsson, K., Rimm, E.B., Stampfer, M.J., Willett, W.C., Giovannucci, E., et al. (2001). A prospective study on intake of animal products and risk of prostate cancer. *Cancer Causes Control*, 12(6), 557-567.
124. Ramon, J.M., Bou, R., Romea, S., Alkiza, M.E., Jacas, M., Ribes, J., et al. (2000). Dietary fat intake and prostate cancer risk: a case-control study in Spain. *Cancer Causes Control*, 11(8), 679-685.
125. Lemaitre, R.N., King, I.B., & Raghunathan, T.E. (2002). Cell membrane trans-fatty acids and the risk of primary cardiac arrest. *Circulation*, 105, 697-701.
126. Katan, M.B. (2000). Trans fatty acids and plasma lipoproteins. *Nutrition Reviews*, 58, 188-191.
127. Mensink R.P., & Katan M.B. (1990). Effect of dietary trans fatty acids on high-density and low-density lipoprotein cholesterol levels in healthy subjects. *New England Journal of Medicine*, 323, 439-445.
128. Nelson, G.J. (1998). Dietary fat, trans fatty acids, and risk of coronary heart disease. *Nutrition Reviews*, 56, 250-252.
129. Bakker, N., Van't Veer, P., & Zock, P.L. (1997). Adipose fatty acids and cancers of the breast, prostate and colon: an ecological study. EURAMIC Study Group. *International Journal of Cancer*, 72(4), 587-591.
130. Slattery, M.L., Benson, J., Ma, K.N., Schaffer, D., & Potter, J.D. (2001). Trans-fatty acids and colon cancer. *Nutrition and Cancer*, 39(2), 170-175.
131. Hughes-Fulford, M., Chen, Y., & Tjandrawinata, R.R. (2001). Fatty acid regulates gene expression and growth of human prostate cancer PC-3 cells. *Carcinogenesis*, 22(5), 701-707.
132. Norrish, A.E., Jackson, R.T., Sharpe, S.J., & Skeaff, C.M. (2000). Men who consume vegetable oils rich in monounsaturated fat: their dietary patterns and risk of prostate cancer (New Zealand). *Cancer Causes Control*, 11(7), 609-615.
133. Gonzalez, C.A. & Salas-Salvado, J. (2006). The potential of nuts in the prevention of cancer. *British Journal of Nutrition*, 96 Suppl 2, S87-S94.
134. Lu, Q.Y., Arteaga, J.R., Zhang, Q., Huerta, S., Go, V.L., et al. (2005). Inhibition of prostate cancer cell growth by an avocado extract: role of lipid-soluble bioactive substances. *Journal of Nutritional Biochemistry*, 16(1), 23-30.

135. Mannisto, S., Pietinen, P., Virtanen, M.J., Salminen, I., Albanes, D., Giovannucci, E., Virtamo, J., et al. (2003). Fatty acids and risk of prostate cancer in a nested case-control study in male smokers. *Cancer Epidemiology Biomarkers and Prevention*, 12(12), 1422-1428.
136. Harvei, S., Bjerve, K.S., Tretli, S., Jellum, E., Robsahm, T.E., Vatten, L., et al. (1997). Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. *International Journal of Cancer*, 71(4), 545-551.
137. Gann, P.H., Hennekens, C.H., Sacks, F.M., Grodstein, F., Giovannucci, E.L., Stampfer, M.J., et al. (1994). Prospective study of plasma fatty acids and risk of prostate cancer. *Journal of the National Cancer Institute*, 86(4), 281-286.
138. Newcomer, L.M., King, I.B., Wicklund, K.G., & Stanford, J.L. (2001). The association of fatty acids with prostate cancer risk. *Prostate*, 47(4), 262-268.
139. Godley, P.A., Campbell, M.K., Gallagher, P., Martinson, F.E., Mohler, J.L., Sandler, R.S., et al. (1996). Biomarkers of essential fatty acid consumption and risk of prostatic carcinoma. *Cancer Epidemiology Biomarkers and Prevention*, 5(11), 889-895.
140. Ghosh, J., & Myers, C.E. (1997). Arachidonic acid stimulates prostate cancer cell growth: critical role of 5-lipoxygenase. *Biochemical Biophysical Research Communications*, 235(2), 418-423.
141. Ritch, C.R., Wan, R.L., Stephens, L.B., Taxy, J.B., Huo, D., Gong, E.M., et al. (2007). Dietary fatty acids correlate with prostate cancer biopsy grade and volume in Jamaican men. *Journal of Urology*, 177(1), 97-101.
142. Kelavkar, U.P., Hutzley, J., Dhir, R., Kim, P., Allen, K.G., et al. (2006). Prostate tumor growth and recurrence can be modulated by the omega-6:omega-3 ratio in diet: athymic mouse xenograft model simulating radical prostatectomy. *Neoplasia*, 8(2), 112-124.
143. Berquin, I.M., Min, Y., Wu, R., Wu, J., Perry, D., Cline, J.M., et al. (2007). Modulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acids. *The Journal of Clinical Investigation*, 117(7), 1866-1875.
144. Norrish, A.E., Skeaff, C.M., Arribas, G.L., Sharpe, S.J., & Jackson, R.T. (1999). Prostate cancer risk and consumption of fish oils: a dietary biomarker-based case-control study. *British Journal of Cancer*, 81(7), 1238-1242.
145. Augustsson, K., Michaud, D.S., Rimm, E.B., Leitzmann, M.F., Stampfer, M.J., Willett, W.C., et al. (2003). A prospective study of intake of fish and marine fatty acids and prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, 12(1), 64-67.
146. Terry, P., Lichtenstein, P., Feychting, M., Ahlbom, A., & Wolk, A. (2001). Fatty fish consumption and risk of prostate cancer. *Lancet*, 357(9270), 1764-1766.
147. Terry, P.D., Rohan, T.E., & Wolk, A. (2003). Intakes of fish and marine fatty acids and the risks of cancers of the breast and prostate and of other hormone-related cancers: a review of the epidemiologic evidence. *The American Journal of Clinical Nutrition*, 77(3), 532-543.
148. Chung, B.H., Mitchell, S.H., Zhang, J.S., & Young, C.Y. (2001). Effects of docosahexaenoic acid and eicosapentaenoic acid on androgen-mediated cell growth and gene expression in LNCaP prostate cancer cells. *Carcinogenesis*, 22(8), 1201-1206.
149. Kobayashi, N., Barnard, R.J., Henning, S.M., Flashoff, D., Reddy, S.T., et al. (2006). Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. *Clinical Cancer Research*, 12(15), 4662-4670.
150. Amin, M., Jeyaganth, S., Fahmy, N., Bégin, L.R., Aronson, S., Jacobson, S., et al. (2008). Dietary habits and prostate cancer detection: a case-control study. *Canadian Urological Association Journal*, 2(5), 510-515.
151. Mina, K., Fritschi, L., & Johnson, K.C.; Canadian Cancer Registries Epidemiology Research Group. An inverse association between preserved fish and prostate cancer: results from a population-based case-control study in Canada. *Nutrition and Cancer*, 60(2), 222-226.
152. Hedelin, M., Chang, E.T., Wiklund, F., Bellocchio, R., Klint, A., Adolfsson, J., et al. (2007). Association of frequent consumption of fatty fish with prostate cancer risk is modified by COX-2 polymorphism. *International Journal of Cancer*, 120(2), 398-405.

153. Harris, P.J., Robertson, A.M., Watson, M.E., Triggs, C.M., & Ferguson, L.R. (1993). The effects of soluble-fiber polysaccharides on the adsorption of a hydrophobic carcinogen to an insoluble dietary fiber. *Nutrition and Cancer*, 19(1), 43-54.
154. Davis, B.C., & Kris-Etherton, P.M. (2003). Achieving optimal essential fatty acid status in vegetarians: current knowledge and practical implications. *American Journal of Clinical Nutrition*, 78(3 Suppl), 640S-646S.
155. Gerster, H. (1998). Can adults adequately convert alpha-linolenic acid (18:3n-3) to eicosapentaenoic acid (20:5n-3) and docosahexaenoic acid (22:6n-3)? *International Journal for Vitamin and Nutrition Research*, 68(3), 159-173.
156. Andersson, S.O., Wolk, A., Bergstrom, R., Giovannucci, E., Lindgren, C., Baron, J., et al. (1996). Energy, nutrient intake and prostate cancer risk: a population-based case-control study in Sweden. *International Journal of Cancer*, 68(6), 716-722.
157. De Stefani, E., Deneo-Pellegrini, H., Boffetta, P., Ronco, A., & Mendilaharsu, M. (2000). Alpha-linolenic acid and risk of prostate cancer: a case-control study in Uruguay. *Cancer Epidemiology Biomarkers and Prevention*, 9(3), 335-338.
158. Rohrmann, S., Platz, E.A., Kavanaugh, C.J., Thuita, L., Hoffman, S.C., & Helzlsouer, K.J. (2007). Meat and dairy consumption and subsequent risk of prostate cancer in a US cohort study. *Cancer Causes Control*, 18(1), 41-50.
159. Rodriguez, C., McCullough, M.L., Mondul, A.M., Jacobs, E.J., Chao, A., Patel, A.V., et al. (2006). Meat consumption among Black and White men and risk of prostate cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiology and Biomarkers Prevention*, 15(2), 211-216.
160. Koutros, S., Cross, A.J., Sandler, D.P., Hoppin, J.A., Ma, X., Zheng, T., et al. (2008). Meat and meat mutagens and risk of prostate cancer in the Agricultural Health Study. *Cancer Epidemiology and Biomarkers Prevention*, 17(1), 80-87.
161. Allen, N.E., Key, T.J., Appleby, P.N., Travis, R.C., Roddam, A.W., Tjønneland, A., et al. (2008). Animal foods, protein, calcium and prostate cancer risk: the European Prospective Investigation into Cancer and Nutrition. *British Journal of Cancer*, 98(9), 1574-1581.
162. Kurahashi N, Inoue M, Iwasaki M, Sasazuki S, Tsugane AS; Japan Public Health Center Based Prospective Study Group. Collaborators (102). (2008). Dairy product, saturated fatty acid, and calcium intake and prostate cancer in a prospective cohort of Japanese men. *Cancer Epidemiology and Biomarkers Prevention*, 17(4), 930-937.
163. Ahn, J., Albanes, D., Peters, U., Schatzkin, A., Lim, U., Freedman, M., et al.; Prostate, Lung, Colorectal, and Ovarian Trial Project Team. (2007). Dairy products, calcium intake, and risk of prostate cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. *Cancer Epidemiology and Biomarkers Prevention*, 16(12), 2623-2630.
164. Park, Y., Mitrou, P.N., Kipnis, V., Hollenbeck, A., Schatzkin, A., & Leitzmann, M.F. (2007). Calcium, dairy foods, and risk of incident and fatal prostate cancer: the NIH-AARP Diet and Health Study. *American Journal of Epidemiology*, 166(11), 1270-1279.
165. Qin, L.Q., Xu, J.Y., Wang, P.Y., Tong, J., & Hoshi, K. (2007). Milk consumption is a risk factor for prostate cancer in Western countries: evidence from cohort studies. *Asia Pacific Journal of Clinical Nutrition*, 16(3), 467-476.
166. Grant, W.B. (1999). An ecologic study of dietary links to prostate cancer. *Alternative Medicine Reviews*, (3), 162-169.
167. Gao, X., LaValley, M.P., & Tucker, K.L. (2005). Prospective studies of dairy product and calcium intakes and prostate cancer risk: a meta-analysis. *Journal of the National Cancer Institute*, 97(23), 1768-1777.
168. Kesse, E., Bertrais, S., Astorg, P., Jauoen, A., & Arnault, N. (2006). Dairy products, calcium and phosphorus intake, and the risk of prostate cancer: results of the French prospective SU.VI.MAX (Supplementation en Vitamines et Mineraux Antioxydants) study. *British Journal of Nutrition*, 95(3), 539-545.
169. Tseng, M., Breslow, R.A., Graubard, B.I., & Ziegler, R.G. (2005). Dairy, calcium, and vitamin D intakes and prostate cancer risk in the National Health and Nutrition Examination Epidemiologic Follow-up Study cohort. *American Journal of Clinical Nutrition*, 81(5), 1147-1154.
170. McGreevy, K.M., Hoel, B.D., Lipsitz, S.R., & Hoel, D.G. (2007). Impact of nutrients on insulin-like growth factor-I, insulin-like growth factor binding protein-3 and their ratio in African American and white males. *Public Health Nutrition*, 10(1), 97-105.
171. Gunnell, D., Oliver, S.E., Peters, T.J., Donovan, J.L., Persad, R., Maynard, M., et al. (2003). Are diet-prostate cancer associations mediated by the IGF axis? A cross-sectional analysis of diet, IGF-I and IGFBP-3 in healthy middle-aged men. *British Journal of Cancer*, 88(11), 1682-1686.

172. Kristal, A.R., Cohen, J.H., Qu, P., & Stanford, J.L. (2002). Associations of energy, fat, calcium, and vitamin D with prostate cancer risk. *Cancer Epidemiology Biomarkers and Prevention*, 11(8), 719-725.
173. Giovannucci, E., Rimm, E.B., Wolk, A., Ascherio, A., Stampfer, M.J., Colditz, G.A., et al. (1998). Calcium and fructose intake in relation to risk of prostate cancer. *Cancer Research*, 58(3), 442-447.
174. Giovannucci, E., Liu, Y., Stampfer, M.J., & Willett, W.C. (2006). A prospective study of calcium intake and incident and fatal prostate cancer. *Cancer Epidemiology and Biomarkers Prevention*, 15(2), 203-210.
175. Giovannucci, E. (2005). The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). *Cancer Causes Control*, 16(2), 83-95.
176. Koh, K.A., Sesso, H.D., Paffenbarger, R.S. Jr., & Lee, I.M. (2006). Dairy products, calcium and prostate cancer risk. *British Journal of Cancer*, 95(11), 1582-1585.
177. Huncharek, M., Muscat, J., & Kupelnick, B. (2008). Dairy products, dietary calcium and vitamin D intake as risk factors for prostate cancer: a meta-analysis of 26,769 cases from 45 observational studies. *Nutrition and Cancer*, 60(4), 421-441.
178. Mitrou, P.N., Albanes, D., Weinstein, S.J., Pietinen, P., Taylor, P.R., Virtamo, J., et al. (2007). A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). *International Journal of Cancer*, 120(11), 2466-2473.
179. Park, S.Y., Murphy, S.P., Wilkens, L.R., Stram, D.O., Henderson, B.E., & Kolonel, L.N. (2007). Calcium, vitamin D, and dairy product intake and prostate cancer risk: the Multiethnic Cohort Study. *American Journal of Epidemiology*, 166(11), 1259-1269.
180. Pierce, J.P., Faerber, S., Wright, F.A., Rock, C.L., Newman, V., Flatt, S.W., et al. (2002). A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. *Controlled Clinical Trials*, 23(6), 728-756.
181. Vikse, R., Reistad, R., Steffensen, I.L., Paulsen, J.E., Nyholm, S.H., Alexander, J., et al. (1999). [Heterocyclic amines in cooked meat] [Article in Norwegian] *Tidsskrift for den Norske Laegeforening*, 119(1), 45-49.
182. Shirai, T., Imaida, K., & Ito, N. (2000). Prostate. In: M. Nagao and T. Sugimura (Eds.), *Food Born Carcinogenesis. Current Toxicology Series*, (pp. 270-274). Wiley, Chichester.
183. Shirai, T., Sano, M., Tamano, S., Takahashi, S., Hirose, M., Futakuchi, M., et al. (1997). The prostate: a target for carcinogenicity of 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) derived from cooked foods. *Cancer Research*, 57, 195-198.
184. Cui, L., Takahashi, S., Tada, M., Kato, K., Yamada, Y., Kohri, K., et al. (2000). Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Results with 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2'-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity. *Japanese Journal of Cancer Research*, 91, 52-58.
185. Nowell, S., Ratnasinghe, D.L., Ambrosone, C.B., Williams, S., Teague-Ross, T., Trimble L., et al. (2004). Association of SULT1A1 Phenotype and Genotype with Prostate Cancer Risk in African-Americans and Caucasians. *Cancer Epidemiology Biomarkers Prevention*, 13(2), 270-276.
186. Kooiman, G.G., Martin, F.L., Williams, J.A., Grover, P.L., Phillips, D.H., & Muir, G.H., et al. (2000). The influence of dietary and environmental factors on prostate cancer risk. *Prostate Cancer Prostatic Diseases*, 3(4), 256-258.
187. Hu, J.J., Hall, M.C., Grossman, L., Hedayati, M., McCullough, D.L., Lohman, K., et al. (2004). Deficient nucleotide excision repair capacity enhances human prostate cancer risk. *Cancer Research*, 64(3), 1197-1201.
188. Ferguson, L.R. (2002). Meat consumption, cancer risk and population groups within New Zealand. *Mutation Research*, 506-507, 215-224.
189. Tang, D., Liu, J.J., Rundle, A., Neslund-Dudas, C., Savera, A.T., Bock, C.H., et al. (2007). Grilled meat consumption and PhIP-DNA adducts in prostate carcinogenesis. *Cancer Epidemiology and Biomarkers Prevention*, 16(4), 803-808.
190. Bogen, K.T., Keating, G.A. 2nd., Chan, J.M., Paine, L.J., Simms, E.L., Nelson, D.O., et al. (2007). Highly elevated PSA and dietary PhIP intake in a prospective clinic-based study among African Americans. *Prostate Cancer Prostatic Disease*, 10(3), 261-269.

191. Norrish, A.E., Ferguson, L.R., Knize, M.G., Felton, J.S., Sharpe, S.J., & Jackson R.T. (1999). Heterocyclic amine content of cooked meat and risk of prostate cancer. *Journal of the National Cancer Institute*, 91(23), 2038-2044.
192. Eder, E. (1999). Intraindividual variations of DNA adduct levels in humans. *Mutation Research*, 424(1-2), 249-261.
193. Bogen, K.T., & Keating, G.A. (2001). U.S. dietary exposures to heterocyclic amines. *Journal of Exposure Analysis & Environmental Epidemiology*, (3), 155-168.
194. Wilkinson, G.R. (1997). The effects of diet, aging and disease-states on presystemic elimination and oral drug bioavailability in humans. *Advance Drug Delivery Reviews*, 27(2-3), 129-159.
195. Bagnardi, V., Blangiardo, M., La Vecchia, C., & Corrao, G. (2001). A meta-analysis of alcohol drinking and cancer risk. *British Journal of Cancer*, 85(11), 1700-1705.
196. Middleton Fillmore, K., Chikritzhs, T., Stockwell, T., Bostrom, A., & Pascal, R. (2009). Alcohol use and prostate cancer: a meta-analysis. *Molecular Nutrition and Food Research*, 53(2), 240-255.
197. Rohan, T.E., Howe, G.R., Burch, J.D., & Jain, M. (1995). Dietary factors and risk of prostate cancer: a case-control study in Ontario, Canada. *Cancer Causes Control*, 6(2), 145-154.
198. Hsieh, L.J., Carter, H.B., Landis, P.K., Tucker, K.L., Metter, E.J., Newschaffer, C.J., et al. (2003). Association of energy intake with prostate cancer in a long-term aging study: Baltimore Longitudinal Study of Aging (United States). *Urology*, 61(2), 297-301.
199. Powolny, A.A., Wang, S., Carlton, P.S., Hoot, D.R., & Clinton, S.K. (2008). Interrelationships between dietary restriction, the IGF-I axis, and expression of vascular endothelial growth factor by prostate adenocarcinoma in rats. *Molecular Carcinogenesis*, 47(6), 458-465.
200. Sonntag, W.E., Lynch, C.D., Cefalu, W.T., Ingram, R.L., Bennett, S.A., Thornton, P.L., et al. (1999). Pleiotropic effects of growth hormone and insulin-like growth factor (IGF)-1 on biological aging: inferences from moderate caloric-restricted animals. *The Journal of Gerontology. Series A, Biological Science & Medical Science*, 54(12), B521-B538.
201. Calle. (2003). Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. *The New England Journal of Medicine*, 348, 1625-1638.
202. Freedland, S.J., Bañez, L.L., Sun, L.L., Fitzsimons, N.J., & Moul, J.W. (2009). Obese men have higher-grade and larger tumors: an analysis of the duke prostate center database. *Prostate Cancer Prostatic Disease*, 12(3):259-263.
203. Amling, C.L., Riffenburgh, R.H., Sun, L., Moul, J.W., Lance, R.S., Kusuda, L., et al. (2004). Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. *Journal of Clinical Oncology*, 22(3), 439-445.
204. Freedland, S.J., Aronson, W.J., Kane, C.J., Presti, J.C. Jr, Amling, C.L., Elashoff, D., et al. (2004). Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. *Journal of Clinical Oncology*, 22(3), 446-53.
205. Rodriguez, C., Freedland, S.J., Deka, A., Jacobs, E.J., McCullough, M.L., et al. (2007). Body Mass Index, Weight Change, and Risk of Prostate Cancer in the Cancer Prevention Study II Nutrition Cohort. *Cancer Epidemiology and Biomarkers Prevention*, 16(1), 63-69.
206. Pischon, T., Boeing, H., Weikert, S., Allen, N., Key, T., Johnsen, N.F., et al. Body size and risk of prostate cancer in the European prospective investigation into cancer and nutrition. *Cancer Epidemiology and Biomarkers Prevention*, 17(11), 3252-3261.
207. Bassett, W.W., Cooperberg, M.R., Sadetsky, N., Silva, S., DuChane, J., Pasta, D.J., et al. (2005). Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. *Urology*, 66(5). 1060-1065.
208. Nilsen, T.I., Romundstad, P.R., & Vatten, L.J. (2006). Recreational physical activity and risk of prostate cancer: A prospective population-based study in Norway (the HUNT study). *International Journal of Cancer*, 119(12), 2943-2947.
209. Wiklund F, Lageros YT, Chang E, Bälter K, Johansson JE, Adami HO, Grönberg H. (2008). Lifetime total physical activity and prostate cancer risk: a population-based case-control study in Sweden. *European Journal of Epidemiology*, 23(11), 739-746.
210. Darlington GA, Kreiger N, Lightfoot N, Purdham J, Sass-Kortsak A. (2007). Prostate cancer risk and diet, recreational physical activity and cigarette smoking. *Chronic Diseases in Canada*, 27(4), 145-153.

211. Crespo, C.J., Garcia-Palmieri, M.R., Smit, E., Lee, I.M., McGee, D., Muti, P., et al. (2008). Physical activity and prostate cancer mortality in Puerto Rican men. *Journal of Physical Activity and Health*, 5(6), 918-929.
212. Moore SC, Peters TM, Ahn J, Park Y, Schatzkin A, Albanes D, Ballard-Barbash R, Hollenbeck A, Leitzmann MF. (2008). Physical activity in relation to total, advanced, and fatal prostate cancer. *Cancer Epidemiology and Biomarkers Prevention*, 17(9), 2458-2466.
213. Thorsen L, Courneya KS, Stevinson C, Fosså SD. (2008). A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. *Supportive Care in Cancer*, 16(9), 987-997.
214. Morey MC, Snyder DC, Sloane R, Cohen HJ, Peterson B, Hartman TJ, Miller P, Mitchell DC, Demark-Wahnefried W. (2009). Effects of home-based diet and exercise on functional outcomes among older, overweight long-term cancer survivors: RENEW: a randomized controlled trial. *Journal of the American Medical Association*, 301(18), 1883-1891.
215. Culos-Reed SN, Robinson JL, Lau H, O'Connor K, Keats MR. (2007). Benefits of a physical activity intervention for men with prostate cancer. *Journal of Sport and Exercise Psychology*, 29(1), 118-127.
216. Peters, U., Littman, A.J., Kristal, A.R., Patterson, R.E., Potter, J.D., & White, E. (2008). Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort. *Cancer Causes Control*, 19(1), 75-87.
217. Chan, J.M., Oh, W.K., Xie, W., Regan, M.M., Stampfer, M.J., King, I.B., et al. (2009). Plasma Selenium, Manganese Superoxide Dismutase, and Intermediate- or High-Risk Prostate Cancer. *Journal of Clinical Oncology*, 27(22):3577-3583.
218. Venkateswaran, V., Fleshner, N.E., & Klotz, L.H. (2004). Synergistic effect of vitamin E and selenium in human prostate cancer cell lines. *Prostate Cancer Prostatic Disease*, 7(1), 54-56.
219. Lippman, S.M., Klein, E.A., Goodman, P.J., Lucia, M.S., Thompson, I.M., Ford, L.G., et al. (2009). Effect of selenium and vitamin E on risk of prostate cancer and other cancers: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). *Journal of the American Medical Association*, 301(1), 39-51. 224.
220. Clark, L.C., Dalkin, B., Krongrad, A., Combs, G.F. Jr., Turnbull, B.W., Slate, E.H., et al. (1998). Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial. *British Journal of Urology*, 81(5), 730-734.
221. Yoshizawa, K., Willett, W.C., Morris, S.J., Stampfer, M.J., Spiegelman, D., Rimm, E.B., et al. (1998). Study of prediagnostic selenium level in toenails and the risk of advanced prostate cancer. *Journal of the National Cancer Institute*, 90(16), 1219-1224.
222. Hartman, T.J., Dorgan, J.F., Woodson, K., Virtamo, J., Tangrea, J.A., Heinonen, O.P., et al. (2001). Effects of long-term alpha-tocopherol supplementation on serum hormones in older men. *Prostate*, 46(1), 33-38.
223. Pourmand, G., Salem, S., Moradi, K., Nikoobakht, M.R., Tajik, P., & Mehrsai, A. (2008). Serum selenium level and prostate cancer: a case-control study. *Nutrition and Cancer*, 60(2), 171-176.
224. Corcoran, N.M., Najdovska, M., & Costello, A.J. (2004). Inorganic selenium retards progression of experimental hormone refractory prostate cancer. *Journal of Urology*, 171(2 Pt 1), 907-910.
225. Sinha, R., & El-Bayoumy, K. (2004). Apoptosis is a Critical Cellular Event in Cancer Chemoprevention and Chemotherapy by Selenium Compounds. *Current Cancer Drug Targets*, 4(1), 13-28.
226. Peters, U., Foster, C.B., Chatterjee, N., Schatzkin, A., Reding, D., Andriole, G.L., et al. (2007). Serum selenium and risk of prostate cancer—a nested case-control study. *American Journal of Clinical Nutrition*, 85(1), 209-217.
227. Brooks, J.D., Metter, E.J., Chan, D.W., Sokoll, L.J., Landis, P., Nelson, et al. (2001). Plasma selenium level before diagnosis and the risk of prostate cancer development. *Journal of Urology*, 166(6), 2034-2038.
228. Gill, J.K., Franke, A.A., Steven Morris, J., Cooney, R.V., Wilkens, L.R., Le Marchand, L., et al. (2009). Association of selenium, tocopherols, carotenoids, retinol, and 15-isoprostane F(2t) in serum or urine with prostate cancer risk: the multiethnic cohort. *Cancer Causes Control*. 18(7), 1962-1970.
229. Allen, N.E., Appleby, P.N., Roddam, A.W., Tjønneland, A., Johnsen, N.F., Overvad, K., et al. (2008). Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC). *American Journal of Clinical Nutrition*, 88(6), 1567-1575.

230. Bekaert, B., & Rayman, M.P. (2009). Plasma selenium concentration and prostate cancer risk. *American Journal of Clinical Nutrition*, 89(4), 1276-1277.
231. Fairweather-Tait, S., & Hurst, R. (2009). Plasma selenium concentration and prostate cancer risk: effects are dependent on the level of exposure. *American Journal of Clinical Nutrition*, 89(3), 927-928.
232. Bounous, G., & Molson, J.H. (2003). The antioxidant system. *Anticancer Research*, 23(2B), 1411-1415.
233. Combs, G.F. Jr., Clark, L.C., & Turnbull, B.W. (1997). Reduction of cancer risk with an oral supplement of selenium. *Biomedical Environmental Sciences*, 10(2-3), 227-234.
234. Yoshida, M., Sugihara, S., Suenaga, T., Naito, C., Fukunaga, K., Tsuchita, H., et al. (2002). Digestibility and chemical species of selenium contained in high-selenium yeast. *Journal of Nutritional Science and Vitaminology (Tokyo)*, 48(5), 401-404.
235. Schrauzer, G.N. (2001). Nutritional selenium supplements: product types, quality, and safety. *Journal of the American College of Nutrition*, 20(1), 1-4.
236. Kristal, A.R., Stanford, J.L., Cohen, J.H., Wicklund, K., & Patterson, R.E. (1999). Vitamin and mineral supplement use is associated with reduced risk of prostate cancer. *Cancer Epidemiology Biomarkers and Prevention*, 8(10), 887-892.
237. Maramag, C., Menon, M., Balaji, K.C., Reddy, P.G., & Laxmanan, S. (1997). Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability, and DNA synthesis. *Prostate*, 32(3), 188-195.
238. Bidoli, E., Talamini, R., Zucchetto, A., Bosetti, C., Negri, E., Lenardon, O., et al. (2009). Dietary vitamins E and C and prostate cancer risk. *Acta Oncologica*, [Epub ahead of print]
239. Getzenberg, R.H., Light, B.W., Lapco, B.W., Konety B.R., Nangia A.K., Acierno J.S., et al. (1997). Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. *Urology*, 50, 999-1006.
240. Schwartz, G.G., Oeler, T.A., Uskokovic, M.R., & Bahnson, R.R. (1994). Human prostate cancer cells: inhibition of proliferation by vitamin D analogs. *Anticancer Research*, 14, 1077-1081.
241. Lokeshwar, B.L., Schwartz, G.G., Selzer, M.G., Burnstein, K.L., Zhuang, S.H., & Block, N.L., et al. (1999). Inhibition of prostate cancer metastasis in vivo: a comparison of 1,23-dihydroxyvitamin D (calcitriol) and EB1089. *Cancer Epidemiology Biomarkers Prevention*, 8(3), 241-248.
242. Blutt, S.E., Polek, T.C., Stewart, L.V., Kattan, M.W., & Weigel, N.L. (2000). A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. *Cancer Research*, 60(4), 779-782.
243. Vegesna, V., O'Kelly, J., Said, J., Uskokovic, M., Binderup, L., Koeffle, H.P., et al. (2003). Ability of potent vitamin D3 analogs to inhibit growth of prostate cancer cells in vivo. *Anticancer Research*, 23(1A), 283-289.
244. Ahonen, M.H., Tenkanen, L., Teppo, L., Hakama, M., & Tuohimaa, P. (2000). Prostate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). *Cancer Causes Control*, 11(9), 847-852.
245. Tuohimaa, P., Tenkanen, L., Ahonen, M., Lumme, S., Jellum, E., Hallmans, G., et al. (2004). Both high and low levels of blood vitamin D are associated with a higher prostate cancer risk: a longitudinal, nested case-control study in the Nordic countries. *International Journal of Cancer*, 108(1), 104-108.
246. Peehl, D.M., Krishnan, A.V., & Feldman, D. (2003). Pathways mediating the growth-inhibitory actions of vitamin D in prostate cancer. *Journal of Nutrition*, 133(7 Suppl), 2461S-2469S.
247. Studzinski, G.P., & Moore, D.C. (1995). Sunlight--can it prevent as well as cause cancer? *Cancer Research*, 55(18), 4014-4022.
248. Gross, C., Stamey, T., Hancock, S., & Feldman, D. (1998). Treatment of early recurrent prostate cancer with 1,25-dihydroxyvitamin D3 (calcitriol) *Journal of Urology*, 159(6), 2035-2039.
249. Chen, T.C., Wang, L., Whitlatch, L.W., Flanagan, J.N., & Holick, M.F. (2003). Prostatic 25-hydroxyvitamin D-1alpha-hydroxylase and its implication in prostate cancer. *Journal of Cell Biochemistry*, 88(2), 315-322.
250. John, E.M., Koo, J., & Schwartz, G.G. (2007). Sun exposure and prostate cancer risk: evidence for a protective effect of early-life exposure. *Cancer Epidemiology and Biomarkers Prevention*, 16(6), 1283-1286.
251. Hanchette, C.L., & Schwartz, G.G. (1992). Geographic patterns of prostate cancer mortality. Evidence for a protective effect of ultraviolet radiation. *Cancer*, 70(12), 2861-2869.

252. Corder, E.H., Guess, H.A., Hulka, B.S., Friedman, G.D., Sadler, M., Vollmer, R.T., et al. (1993). Vitamin D and prostate cancer: a prediagnostic study with stored sera. *Cancer Epidemiology, Biomarkers and Prevention*, 2(5), 467-472.
253. Giovannucci, E., Liu, Y., Rimm, E.B., Hollis, B.W., Fuchs, C.S., et al. (2006). Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. *Journal of the National Cancer Institute*, 98(7), 451-459.
254. Cooney, R.V., Franke, A.A., Wilkens, L.R., Gill, J., & Kolonel, L.N. (2008). Elevated plasma gamma-tocopherol and decreased alpha-tocopherol in men are associated with inflammatory markers and decreased plasma 25-OH vitamin D. *Nutrition and Cancer*, 60 Suppl 1, 21-29.
255. Ahn, J., Peters, U., Albanes, D., Purdue, M.P., Abnet, C.C., Chatterjee, N., et al.; Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial Project Team. (2008). Serum vitamin D concentration and prostate cancer risk: a nested case-control study. *Journal of the National Cancer Institute*, 100(11), 796-804.
256. Faupel-Badger, J.M., Diaw, L., Albanes, D., Virtamo, J., Woodson, K., & Tangrea, J.A. (2007). Lack of association between serum levels of 25-hydroxyvitamin D and the subsequent risk of prostate cancer in Finnish men. *Cancer Epidemiology and Biomarkers Prevention*, 16(12), 2784-2786.
257. Travis, R.C., Crowe, F.L., Allen, N.E., Appleby, P.N., Roddam, A.W., Tjønneland, A., et al. (2009). Serum vitamin D and risk of prostate cancer in a case-control analysis nested within the European Prospective Investigation into Cancer and Nutrition (EPIC). *American Journal of Epidemiology*, 169(10), 1223-1232.
258. Tretli, S., Hernes, E., Berg, J.P., Hestvik, U.E., & Røksahm, T.E. (2009). Association between serum 25(OH)D and death from prostate cancer. *British Journal of Cancer*, 100(3), 450-454.
259. Holick, M.F. (2008). Vitamin D and sunlight: strategies for cancer prevention and other health benefits. *Clinical Journal of the American Society of Nephrology*, 3(5), 1548-1554.
260. Beer, T.M. (2003). Development of weekly high-dose calcitriol based therapy for prostate cancer. *Urology Oncology*, 21(5), 399-405.
261. Li, H., Stampfer, M.J., Hollis, J.B., Mucci, L.A., Gaziano, J.M., Hunter, D., et al. (2007). A prospective study of plasma vitamin D metabolites, vitamin D receptor polymorphisms, and prostate cancer. *PLoS Medicine*, 4(3), e103.
262. Raimondi, S., Johansson, H., Maisonneuve, P., & Gandini, S. (2009). Review and meta-analysis on vitamin D receptor polymorphisms and cancer risk. *Carcinogenesis*, 30(7), 1170-1180.
263. Thomas, M.K., Lloyd-Jones, D.M., Thadhani, R.I., Shaw, A.C., Deraska, D.J., Kitch, B.T., et al. (1998). Hypovitaminosis D in medical inpatients. *New England Journal of Medicine*, 338, 777-778.
264. Rasmussen, L.B., Hansen, G.L., Hansen, E., Koch, B., Mosekilde, L., Molgaard, C., et al. (2000). Vitamin D: should the supply in the Danish population be increased? *International Journal of Food Science Nutrition*, 51(3), 209-215.
265. Webb, A.R., Pilbeam, C., Hanafin, N., & Holick, M.F. (1990). An evaluation of the relative contributions of exposure to sunlight and of diet to the circulating concentrations of 25-hydroxyvitamin D in an elderly nursing home population in Boston. *American Journal of Clinical Nutrition*, 51, 1075-1081.
266. Silverberg, S.J., Shane, E., de la Cruz, L., Segre, C.V., Clemens, T.L., Bilezikian, J.P., et al. (1989). Vitamin D hydroxylation abnormalities in parathyroid hormone secretion and 1,25-dihydroxyvitamin D-3 formation in women with osteoporosis. *New England Journal of Medicine*, 320, 277-281.
267. Ebeling, P.R., Sandgren, M.E., DiMaggio, E.P., Lane, A.W., DeLuca, H.F., Riggs B.L., et al. (1992). Evidence of an age-related decrease in intestinal responsiveness to vitamin D: relationship between serum 1,25-dihydroxyvitamin D-3 and intestinal vitamin D receptor concentrations in normal women. *Journal of Clinical Endocrinology Metabolism*, 75, 176-182.
268. Bischoff-Ferrari, H.A., Giovannucci, E., Willett, W.C., Dietrich, T., & Dawson-Hughes, B. (2006). Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. *American Journal of Clinical Nutrition*, 84(1), 18-28.
269. Helzlsouer, K.J., Huang, H.Y., Alberg, A.J., Hoffman, S., Burke, A., & Norkus, E.P., et al. (2000). Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. *Journal of National Cancer Institute*, 92(24), 2018-2023.

270. Huang, H.Y., Alberg, A.J., Norkus, E.P., Hoffman, S.C., Comstock, G.W., Helzlsouer, K.J., et al. (2003). Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. *American Journal of Epidemiology*, 157(4), 335-344.
271. Nomura, A.M., Stemmermann, G.N., Lee, J., & Craft, N.E. (1997). Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. *Cancer Epidemiology Biomarkers Prevention*, 6(7), 487-491.
272. Chopra, R.K., & Bhagavan, H.N. (1999). Relative bioavailabilities of natural and synthetic vitamin E formulations containing mixed tocopherols in human subjects. *International Journal of Vitamin Nutrition Research*, 69(2), 92-95.
273. Handelman, G.J., Epstein, W.L., Pearson, J., Spiegelman, D., Machlin, L.J., & Dratz, E.A. (1994). Human adipose alpha-tocopherol and gamma-tocopherol kinetics during and after 1 y of alpha-tocopherol supplementation. *American Journal of Clinical Nutrition*, 59(5), 1025-1032.
274. Handelman, G.J., Machlin, L.J., Fitch, K., Weiter, J.J., & Dratz, E.A. (1985). Oral alpha-tocopherol supplements decrease plasma gamma-tocopherol levels in humans. *Journal of Nutrition*, 115(6), 807-813.
275. Moyad, M.A., Brumfield, S.K., & Pienta, K.J. (1999). Vitamin E, alpha- and gamma-tocopherol, and prostate cancer. *Seminars in Urologic Oncology*, 17(2), 85-90.
276. Zu, K., & Ip, C. (2003). Synergy between selenium and vitamin E in apoptosis induction is associated with activation of distinctive initiator caspases in human prostate cancer cells. *Cancer Research*, 63(20), 6988-6995.
277. Jiang, Q., Christen, S., Shigenaga, M.K., & Ames, B.N. (2001). Gamma-tocopherol, the major form of vitamin E in the US diet, deserves more attention. *American Journal of Clinical Nutrition*, 74(6), 714-722.
278. Galli, F., Stabile, A.M., Betti, M., Conte, C., Pistilli, A., Rende, M., et al. (2004). The effect of alpha- and gamma-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. *Archives of Biochemistry & Biophysics*, 423(1), 97-102.
279. Sigounas, G., Anagnostou, A., & Steiner, M. (1997). dl-alpha-tocopherol induces apoptosis in erythroleukemia, prostate, and breast cancer cells. *Nutrition and Cancer*, 28(1), 30-35.
280. Malafa, M.P., Fokum, F.D., Andoh, J., Neitzel, L.T., Bandyopadhyay, S., et al. (2006). Vitamin E succinate suppresses prostate tumor growth by inducing apoptosis. *International Journal of Cancer*, 118(10), 2441-2447.
281. Lawson, K.A., Wright, M.E., Subar, A., Mouw, T., Hollenbeck, A., Schatzkin, A., et al. (2007). Multivitamin use and risk of prostate cancer in the National Institutes of Health-AARP Diet and Health Study. *Journal of the National Cancer Institute*, 99(10), 754-764.
282. Dabrosin, C., Chen, J., Wang, L., & Thompson, L.U. (2002). Flaxseed inhibits metastasis and decreases extracellular vascular endothelial growth factor in human breast cancer xenografts. *Cancer Letters*, 185(1), 31-37.
283. Demark-Wahnefried, W., Price, D.T., Polascik, T.J., Robertson, C.N., Anderson, E.E., Paulson, D.F., et al. (2001). Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. *Urology*, 58(1), 47-52.
284. Denis, L., Morton, M.S., & Griffiths, K. (1999). Diet and its preventive role in prostatic disease. *European Urology*, 35(5-6), 377-387.
285. Lin, X., Gingrich, J.R., Bao, W., Li, J., Haroon, Z.A., Demark-Wahnefried, W., et al. (2002). Effect of flaxseed supplementation on prostatic carcinoma in transgenic mice. *Urology*, 60(5), 919-924.
286. Moyad, M.A. (2000). *The ABCs of nutrition and supplements for prostate cancer*. Ann Arbor, MI: JW Edwards Publishing.
287. Demark-Wahnefried, W., Polascik, T.J., George, S.L., Switzer, B.R., Madden, J.F., Ruffin, M.T. 4th, et al. (2008). Flaxseed supplementation (not dietary fat restriction) reduces prostate cancer proliferation rates in men presurgery. *Cancer Epidemiology and Biomarkers Prevention*, 17(12), 3577-3587.
288. Leone, M., Zhai, D., Sareth, S., Kitada, S., Reed, J.C., & Pellicchia, M. (2003). Cancer prevention by tea polyphenols is linked to their direct inhibition of antiapoptotic Bcl-2-family proteins. *Cancer Research*, 63(23), 8118-8121.
289. Takabayashi, F., Tahara, S., Kaneko, T., & Harada, N. (2004). Effect of green tea catechins on oxidative DNA damage of hamster pancreas and liver induced by N-Nitrosobis(2-oxopropyl)amine and/or oxidized soybean oil. *Biofactors*, 21(1-4), 335-337.

290. Gleib, M., & Pool-Zobel, B.L. (2006). The main catechin of green tea, (-)-epigallocatechin-3-gallate (EGCG), reduces bleomycin-induced DNA damage in human leucocytes. *Toxicology In Vitro*, 20(3), 295-300.
291. Stuart, E.C., Scandlyn, M.J., & Rosengren, R.J. (2006). Role of epigallocatechin gallate (EGCG) in the treatment of breast and prostate cancer. *Life Sciences*, 79(25), 2329-2336.
292. Crespy, V., & Williamson, G. (2004). A review of the health effects of green tea catechins in in vivo animal models. *Journal of Nutrition*, 134(12 Suppl), 3431S-3440S.
293. Siddiqui, I.A., Saleem, M., Adhami, V.M., Asim, M., & Mukhtar, H. (2007). Tea beverage in chemoprevention and chemotherapy of prostate cancer. *Acta Pharmacologica Sinica*, 28(9), 1392-1408.
294. Hussain, T., Gupta, S., Adhami, V.M., & Mukhtar, H. (2005). Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *International Journal of Cancer*, 113(4), 660-669.
295. Patel, S.P., Hotston, M., Kommu, S., & Persad, R.A. (2005). Green tea constituent epigallocatechin-3-gallate selectively inhibits COX-2 without affecting COX-1 expression in human prostate carcinoma cells. *International Journal of Cancer*, 113(4), 660-669.
296. Saleem, M., Adhami, V.M., Siddiqui, I.A., & Mukhtar, H. (2003). Tea beverage in chemoprevention of prostate cancer: a mini-review. *Nutrition Cancer*, 47(1), 13-23.
297. Gupta, S., Hussain, T., & Mukhtar, H. (2003). Molecular pathway for (-)-epigallocatechin-3-gallate-induced cell cycle arrest and apoptosis of human prostate carcinoma cells. *Archives of Biochemistry and Biophysics*, 410(1), 177-185.
298. Jian, L., Xie, L.P., Lee, A.H., & Binns, C.W. (2004). Protective effect of green tea against prostate cancer: a case-control study in southeast China. *International Journal of Cancer*, 108(1), 130-135.
299. Lee, A.H., Fraser, M.L., Meng, X., & Binns, C.W. (2006). Protective effects of green tea against prostate cancer. *Expert Reviews of Anticancer Therapies*, 6(4), 507-513.
300. Yu, H.N., Yin, J.J., & Shen, S.R. (2004). Growth inhibition of prostate cancer cells by epigallocatechin gallate in the presence of Cu²⁺. *Journal of Agricultural Food Chemistry*, 52(3), 462-466.
301. Brusselmans, K., De Schrijver, E., Heyns, W., Verhoeven, G., & Swinnen, J.V. (2003). Epigallocatechin-3-gallate is a potent natural inhibitor of fatty acid synthase in intact cells and selectively induces apoptosis in prostate cancer cells. *International Journal of Cancer*, 106(6), 856-862.
302. Chung, L.Y., Cheung, T.C., Kong, S.K., Fung, K.P., Choy, Y.M., Chan, Z.Y., et al. (2001). Induction of apoptosis by green tea catechins in human prostate cancer DU145 cells. *Life Sciences*, 68(10), 1207-1214.
303. Hastak, K., Gupta, S., Ahmad, N., Agarwal, M.K., Agarwal, M.L., Mukhtar, H., et al. (2003). Role of p53 and NF-kappaB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. *Oncogene*, 22(31), 4851-4859.
304. Gupta, S., Srivastava, M., Ahmad, N., Sakamoto, K., Bostwick, D.G., Mukhtar, H., et al. (2001). Lipoxygenase-5 is overexpressed in prostate adenocarcinoma. *Cancer*, 91(4), 737-743.
305. Lee, S.C., Chan, W.K., Lee, T.W., Lam, W.H., Wang, X., Chan, T.H., et al. (2008). Effect of a prodrug of the green tea polyphenol (-)-epigallocatechin-3-gallate on the growth of androgen-independent prostate cancer in vivo. *Nutrition and Cancer*, 60(4), 483-491.
306. Jatoi, A., Ellison, N., Burch, P.A., Sloan, J.A., Dakhil, S.R., Novotny, P., et al. (2003). A phase II trial of green tea in the treatment of patients with androgen independent metastatic prostate carcinoma. *Cancer*, 97(6), 1442-1446.
307. Kikuchi, N., Ohmori, K., Shimazu, T., Nakaya, N., Kuriyama, S., et al. (2006). No association between green tea and prostate cancer risk in Japanese men: the Ohsaki Cohort Study. *British Journal of Cancer*, 95(3), 371-373.
308. Kurahashi, N., Sasazuki, S., Iwasaki, M., Inoue, M., & Tsugane, S.; JPHC Study Group. (2007). Green tea consumption and prostate cancer risk in Japanese men: a prospective study. *American Journal of Epidemiology*, 167(1), 71-77.
309. Zhou, J.R., Yu, L., Zhong, Y., & Blackburn, G.L. (2003). Soy phytochemicals and tea bioactive components synergistically inhibit androgen-sensitive human prostate tumors in mice. *Journal of Nutrition*, 133(2), 516-521.

310. McLarty, J., Bigelow, R.L., Smith, M., Elmajian, D., Ankem, M., & Cardelli, J.A. (2009). Tea Polyphenols Decrease Serum Levels of Prostate-Specific Antigen, Hepatocyte Growth Factor, and Vascular Endothelial Growth Factor in Prostate Cancer Patients and Inhibit Production of Hepatocyte Growth Factor and Vascular Endothelial Growth Factor In vitro. *Cancer Prevention Research (Phila Pa)*, 2(7), 673-682.
311. Jenkins, D.J., Kendall, C.W., D'Costa, M.A., Jackson, C.J., Vidgen, E., Singer W., et al. (2003). Soy consumption and phytoestrogens: effect on serum prostate specific antigen when blood lipids and oxidized low-density lipoprotein are reduced in hyperlipidemic men. *Journal of Urology*, 169(2), 507-511.
312. McCarty, M.F. (1999). Vegan proteins may reduce risk of cancer, obesity, and cardiovascular disease by promoting increased glucagon activity. *Medical Hypotheses*, 53(6), 459-485.
313. Arliss, R.M., & Biermann, C.A. (2002). Do soy isoflavones lower cholesterol, inhibit atherosclerosis, and play a role in cancer prevention? *Holistic Nursing Practice*, 16(5), 40-48.
314. Setchell, K.D., & Lydeking-Olsen, E. (2003). Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. *American Journal of Clinical Nutrition*, 78(3 Suppl), 593S-609S.
315. Ho, SC., Woo, J., Lam, S., Chen, Y., Sham, A., Lau, J., et al. (2003). Soy protein consumption and bone mass in early postmenopausal Chinese women. *Osteoporosis International*, 14(10), 835-842.
316. Messina, M.J., Persky, V., Setchell, K.D., & Barnes, S. (1994). Soy intake and cancer risk: a review of the in vitro and in vivo data. *Nutrition Cancer*, 21, 113-131.
317. Zhou, J.R., Yu, L., Zhong, Y., Nassr, R.L., Franke, A.A., Gaston S.M., et al. (2002). Inhibition of orthotopic growth and metastasis of androgen-sensitive human prostate tumors in mice by bioactive soybean components. *Prostate*, Oct 1, 53(2), 143-153.
318. Messina, M.J. (2003). Emerging evidence on the role of soy in reducing prostate cancer risk. *Nutrition Reviews*, 61(4), 117-131.
319. Pollard, M., & Wolter, W. (2000). Prevention of spontaneous prostate-related cancer in Lobund-Wistar rats by a soy protein isolate/isoflavone diet. *Prostate*, 45(2), 101-105.
320. Jacobsen, B.K., Knutsen, S.F., & Fraser, G.E. (1998). Does high soy milk intake reduce prostate cancer incidence? The Adventist Health Study (United States). *Cancer Causes & Control*, 9, 553-557.
321. Aronson, W.J., Tymchuk, C.N., Elashoff, R.M., McBride, W.H., McLean, C., Wang, H., et al. (1999). Decreased growth of human prostate LNCaP tumors in SCID mice fed a low-fat, soy protein diet with isoflavones. *Nutrition and Cancer*, 35(2), 130-136.
322. Li, X.M., Li, J., Tsuji, I., Nakaya, N., Nishino, Y., & Zhao, X.J. (2008). Mass screening-based case-control study of diet and prostate cancer in Changchun, China. *Asian Journal of Andrology*, 10(4), 551-560.
323. Yan, L., & Spitznagel, E.L. (2009). Soy consumption and prostate cancer risk in men: a revisit of a meta-analysis. *American Journal of Clinical Nutrition*, 89(4), 1155-1163.
324. Yan, L. & Spitznagel, E.L. (2005). Meta-analysis of soy food and risk of prostate cancer in men. *International Journal of Cancer*, 117(4), 667-669.
325. Yi, M.A., Son, H.M., Lee, J.S., Kwon, C.S., Lim, J.K., Yeo, Y.K., et al. (2002). Regulation of male sex hormone levels by soy isoflavones in rats. *Nutrition & Cancer*, 42(2), 206-210.
326. Kurahashi, N., Iwasaki, M., Inoue, M., Sasazuki, S., & Tsugane, S. (2008). Plasma isoflavones and subsequent risk of prostate cancer in a nested case-control study: the Japan Public Health Center. *Journal of Clinical Oncology*, 26(36), 5923-5929.
327. Gardner-Thorpe, D., O'Hagen, C., Young, I., & Lewis, S.J. (2003). Dietary supplements of soya flour lower serum testosterone concentrations and improve markers of oxidative stress in men. *European Journal of Clinical Nutrition*, 57(1), 100-106.
328. Tsutsumi, M., Suzuki, K., Shiga, Y., Ishikawa, S., & Ishikawa, Y. (2002). [A low-fat and high soybean protein diet for patients with elevated serum PSA level: alteration of QOL and serum PSA level after the dietary intervention] [Article in Japanese] *Hinyokika Kyo*, 48(4), 207-211.

329. Moyad, M.A., Sakr, W.A., Hirano, D., & Miller, G.J. (2001). Complementary medicine for prostate cancer: effects of soy and fat consumption. *Reviews of Urology*, 3 Suppl 2, S20-S30.
330. Messina, M., Kucuk, O., & Lampe, J.W. (2006). An overview of the health effects of isoflavones with an emphasis on prostate cancer risk and prostate-specific antigen levels. *Journal of AOAC International*, 89(4), 1121-1134.
331. Singh, R.P., & Agarwal, R. (2004). Prostate cancer prevention by silibinin. *Current Cancer Drug Targets*, 4(1), 1-11.
332. Singh, R.P., Dhanalakshmi, S., Tyagi, A.K., Chan, D.C., Agarwal, C., & Agarwal, R. (2002). Dietary feeding of silibinin inhibits advanced human prostate carcinoma growth in athymic nude mice and increases plasma insulin-like growth factor-binding protein-3 levels. *Cancer Research*, 62(11), 3063-3069.
333. Tyagi, A., Bhatia, N., Condon, M.S., Bosland, M.C., Agarwal, C., & Agarwal, R. (2002). Antiproliferative and apoptotic effects of silibinin in rat prostate cancer cells. *Prostate*, 53(3), 211-217.
334. Tyagi, A.K., Singh, R.P., Agarwal, C., Chan, D.C., & Agarwal, R. (2002). Silibinin strongly synergizes human prostate carcinoma DU145 cells to doxorubicin-induced growth inhibition, G2-M arrest, and apoptosis. *Clinical Cancer Research*, 8(11), 3512-3519.
335. Zi, X., Zhang, J., Agarwal, R., & Pollak, M. (2000). Silibinin up-regulates insulin-like growth factor-binding protein 3 expression and inhibits proliferation of androgen-independent prostate cancer cells. *Cancer Research*, 60(20), 5617-5620.
336. Raina, K., Rajamanickam, S., Singh, R.P., Deep, G., Chittezhath, M., & Agarwal, R. (2008). Stage-specific inhibitory effects and associated mechanisms of silibinin on tumor progression and metastasis in transgenic adenocarcinoma of the mouse prostate model. *Cancer Research*, 68(16), 6822-6830.
337. Mokhtari, M.J., Motamed, N., & Shokrgozar, M.A. (2008). Evaluation of silibinin on the viability, migration and adhesion of the human prostate adenocarcinoma (PC-3) cell line. *Cell Biology International*, 32(8), 888-892.
338. Verschoyle, R.D., Greaves, P., Patel, K., Marsden, D.A., Brown, K., Steward, W.P., et al. (2008). Evaluation of the cancer chemopreventive efficacy of silibinin in genetic mouse models of prostate and intestinal carcinogenesis: relationship with silibinin levels. *European Journal of Cancer*, 44(6), 898-906.
339. Yip, I., Cudiamat, M., & Chim, D. (2003). PC-SPES for treatment of prostate cancer: herbal medicine. *Current Urology Reports*, 4(3), 253-257.
340. Cordell, G.A. (2002). PC-SPES: a brief overview. *Integrative Cancer Therapies*, 1(3), 271-286.
341. Shabbir, M., Love, J., & Montgomery, B. (2008). Phase I trial of PC-Spes2 in advanced hormone refractory prostate cancer. *Oncology Reports*, 19(3), 831-835.
342. Katz, A.E. (2002). Flavonoid and botanical approaches to prostate health. *Journal of Alternative and Complementary Medicine*, 8(6), 813-821.
343. Yang, Y., Ikezoe, T., Zheng, Z., Taguchi, H., Koeffler, H.P., & Zhu, W.G. (2007). Saw Palmetto induces growth arrest and apoptosis of androgen-dependent prostate cancer LNCaP cells via inactivation of STAT 3 and androgen receptor signaling. *International Journal of Oncology*, 31(3), 593-600.
344. Wadsworth, T.L., Worstell, T.R., Greenberg, N.M., & Roselli, C.E. (2007). Effects of dietary saw palmetto on the prostate of transgenic adenocarcinoma of the mouse prostate model (TRAMP). *Prostate*, 67(6):661-673.
345. Goldmann, W.H., Sharma, A.L., Currier, S.J., Johnston, P.D., Rana, A., & Sharma, C.P. (2001). Saw palmetto berry extract inhibits cell growth and Cox-2 expression in prostatic cancer cells. *Cell Biology International*, 25(11), 1117-1124.
346. Bonnar-Pizzorno, R.M., Littman, A.J., Kestin, M., & White, E. (2006). Saw palmetto supplement use and prostate cancer risk. *Nutrition and Cancer*, 55(1), 21-27.
347. Itokawa, H., Shi, Q., Akiyama, T., Morris-Natschke, S.L., & Lee, K.H. (2008). Recent advances in the investigation of curcuminoids. *Chinese Medicine*, 3, 11.
348. Nonn, L., Duong, D., & Peehl, D.M. (2007). Chemopreventive anti-inflammatory activities of curcumin and other phytochemicals mediated by MAP kinase phosphatase-5 in prostate cells. *Carcinogenesis*, 28(6), 1188-1196.
349. Dorai, T., Cao, Y.C., Dorai, B., Buttyan, R., & Katz, A.E. (2001). Therapeutic potential of curcumin in human prostate cancer. III. Curcumin inhibits proliferation, induces apoptosis, and inhibits angiogenesis of LNCaP prostate cancer cells

in vivo. *Prostate*, 47(4), 293-303.

350. Dorai, T., Gehani, N., & Katz, A. (2000). Therapeutic potential of curcumin in human prostate cancer. II. Curcumin inhibits tyrosine kinase activity of epidermal growth factor receptor and depletes the protein. *Molecular Urology*, 4(1), 1-6.
351. Deeb, D., Xu, Y.X., Jiang, H., Gao, X., Janakiraman, N., Chapman, R.A., et al. (2003). Curcumin (diferuloyl-methane) enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in LNCaP prostate cancer cells. *Molecular Cancer Therapeutics*, 2(1), 95-103.
352. Chendil, D., Ranga, R.S., Meigooni, D., Sathishkumar, S., & Ahmed, M.M. (2004). Curcumin confers radiosensitizing effect in prostate cancer cell line PC-3. *Oncogene*, 23(8), 1599-1607.
353. Guo, H., Yu, J.H., Chen, K., Ye, Z.Q., & Liu, G.C. (2006). [Curcumin-induced apoptosis in androgen-dependent prostate cancer cell line LNCaP in vitro] [Article in Chinese] *Zhonghua Nan Ke Xue*, 12(2), 141-144.
354. Huang, M.T., Lou, Y.R., Xie, J.G., Ma, W., Lu, Y.P., Yen, P., et al. (1998). Effect of dietary curcumin and dibenzoylmethane on formation of 7,12-dimethylbenz[a]anthracene-induced mammary tumors and lymphomas/leukemias in Sencar mice. *Carcinogenesis*, 19(9), 1697-1700.
355. Andrzejewski, T., Deeb, D., Gao, X., Danyluk, A., Arbab, A.S., Dulchavsky, S.A., et al. (2008). Therapeutic efficacy of curcumin/TRAIL combination regimen for hormone-refractory prostate cancer. *Oncology Research*, 17(6), 257-267.
356. Piantino, C.B., Salvadori, F.A., Ayres, P.P., Kato, R.B., Srougi, V., Leite, K.R., et al. (2009). An evaluation of the anti-neoplastic activity of curcumin in prostate cancer cell lines. *Int Braz Journal of Urology*, 35(3), 354-360.
357. Wallace, J.M. (2002). Nutritional and botanical modulation of the inflammatory cascade--eicosanoids, cyclooxygenases, and lipoxygenases--as an adjunct in cancer therapy. *Integrative Cancer Therapies*, 1(1), 7-37.
358. Bemis, D.L., Capodice, J.L., Anastasiadis, A.G., Katz, A.E., & Buttyan, R. (2005). Zylamend, a unique herbal preparation with nonselective COX inhibitory activity, induces apoptosis of prostate cancer cells that lack COX-2 expression. *Nutrition and Cancer*, 52(2), 202-212.
359. Capodice, J.L., Gorroochurn, P., Cammack, A.S., Eric, G., McKiernan, J.M., Benson, M.C., et al. (2009). Zylamend in men with high-grade prostatic intraepithelial neoplasia: results of a phase I clinical trial. *Journal of the Society for Integrative Oncology*, 7(2), 43-51.
360. Thompson, C.A., Shanafelt, T.D., & Loprinzi, C.L. (2003). Andropause: symptom management for prostate cancer patients treated with hormonal ablation. *Oncologist*, 8(5), 474-487.
361. Van de Weijer, P.H., & Barentsen, R. (2002). Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. *Maturitas*, 42(3), 187-193.
362. Hernandez Munoz, G., & Pluchino, S. (2003). *Cimicifuga racemosa* for the treatment of hot flushes in women surviving breast cancer. *Maturitas*, 44 (Suppl 1), S59-S65.
363. Messina, M., & Hughes, C. (2003). Efficacy of soyfoods and soybean isoflavone supplements for alleviating menopausal symptoms is positively related to initial hot flush frequency. *Journal of Medicinal Food*, 6(1), 1-11.
364. Smith, M.R. (2004). Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. *Urology*, 63(4), 742-745.
365. Smith, M.R. (2002). Osteoporosis and other adverse body composition changes during androgen deprivation therapy for prostate cancer. *Cancer and Metastasis Reviews*, 21(2), 159-166.
366. Berruti, A., Dogliotti, L., Terrone, C., Cerutti, S., Isaia, G., Tarabuzzi, R., et al. (2002). Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. *Journal of Urology*, 167(6), 2361-2367.
367. Basaria, S., Lieb, J. 2nd, Tang, A.M., DeWeese, T., Carducci, M., Eisenberger, M., et al. (2002). Long-term effects of androgen deprivation therapy in prostate cancer patients. *Clinical Endocrinology*, 56(6), 779-786.
368. Nowicki, M., Bryc, W., & Kokot, F. (2001). Hormonal regulation of appetite and body mass in patients with advanced prostate cancer treated with combined androgen blockade. *Journal of Endocrinological Investigation*, 24(1), 31-36.

369. van Londen, G.J., Levy, M.E., Perera, S., Nelson, J.B., & Greenspan, S.L. (2008). Body composition changes during androgen deprivation therapy for prostate cancer: a 2-year prospective study. *Critical Reviews in Oncology/Hematology*, 68(2), 172-177.
370. Kiratli, B.J., Srinivas, S., Perakash, I., & Terris, M.K. (2001). Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer. *Urology*, 57, 127-132.
371. Daniell, H.W., Dunn, S.R., Ferguson, D.W., Lomas, G., Niazi, Z., Stratte, P.T., et al. (2000). Progressive osteoporosis during androgen deprivation therapy for prostate cancer. *Journal of Urology*, 163, 181-186.
372. Mittan, D., Lee, S., Miller, E., Perez, R.C., Basler, J.W., Bruder, J.M., et al. (2002). Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. *The Journal of Clinical Endocrinology and Metabolism*, 87, 3656-3661.
373. Maillefert, J.F., Sibilia, J., Michel, F., Saussine, C., Javier, R.M., Tavernier, C., et al. (1999). Bone mineral density in men treated with synthetic gonadotropin-releasing hormone agonists for prostatic carcinoma. *Journal of Urology*, 161, 1219-1222.
374. Stoch, S.A., Parker, R.A., Chen, L., Bubley, G., Ko, Y.J., Vincelette, A., et al. (2001). Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists. *Journal of Clinical Endocrinology and Metabolism*, 86, 2787-2791.
375. Wei, J.T., Gross, M., Jaffe, C.A., Gravlin, K., Lahaie, M., Faerber, G.J., et al. (1999). Androgen deprivation therapy for prostate cancer results in significant loss of bone density. *Urology*, 54, 607-611.